Only a few reports have been published on the use of topical antifungal prophylaxis [1] [2] [3] [4] . For this reason we read with interest the paper published by Giglio and colleagues [5] underlining the ability of oral nystatin to reduce fungal colonization in surgical/trauma ICU patients. In our experience, we observed a dramatic increase of candidemia prevalence in neurosurgical ICU patients after implementation of early tracheostomy (from 2.2% to 9.7%). Following an analysis of data collected, we developed the idea that Candida colonization could spread by contiguity from the oropharynx to the trachea and the tracheostomy site. Th e proximity of the trache ostomy to the central venous catheter (CVC) insertion site could be considered a predisposing factor for the development of candidemia. Th erefore, we suggested topical nystatin prophylaxis in order to reduce the inci dence of candidemia. From an operative point of view, we have encouraged prophylactic interventions con sis ting of oral nystatin administration (500,000 IU) along with oral and tracheostomy site brushings four times a day. Th ese measures led to a statistically significant reduction of candidemia during the fi rst 7 months of nystatin use: in detail, while 12 of 124 patients (9.7%) developed at least one laboratory confi rmed candidemia during the whole of 2011, no blood cultures were positive for Candida spp. in 59 patients admitted to the ICU during the period from January to July 2012 (P = 0.01; Figure 1 ). Our preliminary data add another aspect to this line of research: topical nystatin prophylaxis combined with improved CVC management resulted in a signifi cant decrease in incidence of candidemia. Th is result is probably allowed by the reduction of the degree of Candida colonization of the upper respiratory airways in our tracheostomized patients.
Nevertheless, larger clinical trials are needed to understand the real impact of this procedure.
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Th e letter of Ceccarelli and colleagues underlines an important issue in the debate about the prevention of catheter-related bloodstream infections in ICU patients. We agree that the closeness of the tracheostomy to the CVC insertion site could be considered a predisposing factor for the development of candidemia and that by reducing the degree of Candida colonization of the upper respiratory airways in tracheostomized patients, the incidence of candidemia can be decreased. Th ese preliminary data support the idea that what we really need, in order to reduce the incidence of candidemia episodes, are simple, cheap and protocolized strategies. Topical nystatin prophylaxis and a careful management of CVCs are all examples of this kind of intervention. Larger trials are warranted to confi rm this hypothesis.
